Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Tiziana Life Sciences LtdNASDAQ: TLSA

Retained Earnings · Q4 FY2025 · quarter ended Dec 2025

Retained earnings remains negative

Q4 FY2025 retained earnings was -$44.41M, compared with -$144.83M a year earlier.

Context

  • Retained earnings amounted to 386.4% of total assets at the end of Q4 FY2025, down 897.1 pp from a year earlier.
  • Retained earnings grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +69.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$44.41M— QoQ
Last fiscal yearDec 2025
-$44.41M+69.3% YoY
Year agoDec 2024
-$144.83M+69.3% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+69.3%——
1 year+69.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(44.41M) USD
Year-over-year change
+69.3%

Retained Earnings vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's Dec 2025 retained earnings of -$44.41M is the 2nd highest of the 9 companies compared; the peer median is -$260.53M.
  • Its year-over-year change of +69.3% is the highest of 9, against a peer median of -29.4%.
  • Retained earnings amounts to 386.4% of total assets for TLSA, versus a peer median of 459.4%.
TLSA Competitors Peer median
Retained Earnings for TLSA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EXOZeXoZymes, Inc.Mar 2026-$23.47M -70.1%—584.1%
TLSATiziana Life Sciences LtdDec 2025-$44.41M +69.3%—386.4%
COYACoya Therapeutics, Inc.Mar 2026-$69.17M -44.0%—129.8%
IMMXImmix Biopharma, Inc.Mar 2026-$114.55M -44.0%—119.6%
OKYOOKYO Pharma LimitedSep 2025-$145.61M -0.3%—3135.5%
WHWKWhitehawk Therapeutics IncMar 2026-$375.44M -44.6%—295.1%
PLRXPliant Therapeutics, Inc.Mar 2026-$879.44M -14.8%—434.1%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026-$1.23B -11.3%—484.8%
MGNXMacroGenics, Inc.Mar 2026-$1.28B -5.8%—588.0%
Peer median (excluding TLSA) -$260.53M-29.4%—459.4%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents42.19M18.12M1.18M3.72M4.01M
Short-term Investments00000
Net Receivables5.27M5.86M6.05M3.69M4.26M
Inventory00000
Other Current Assets00000
Total Current Assets48.68M24.28M7.34M7.51M8.55M
Property, Plant & Equipment (Net)17K389K293K187K499K
Goodwill00000
Intangible Assets130K0000
Long-term Investments01.81M4.55M3.59M2.44M
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets147K2.2M4.85M3.78M2.94M
Total Assets48.83M26.48M12.18M11.28M11.5M
Account Payables4.41M4.96M4.14M5.58M7.17M
Short-term Debt1.36M0000
Tax Payables00000
Deferred Revenue0000530K
Other Current Liabilities(1.35M)9K14K12K(3K)
Total Current Liabilities7.55M6.66M6.54M7.35M11.21M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities0243K109K0234K
Total Liabilities7.55M6.91M6.65M7.35M11.44M
Common Stock102K102K103K111K121K
Retained Earnings(108.06M)(116.26M)(133.68M)(144.83M)(44.41M)
Accumulated OCI119.15M115.57M117.06M116.99M9.68M
Other Stockholders Equity14.49M5.89M7.13M8.56M0
Minority Interest00000
Total Equity41.28M19.57M5.54M3.94M52K
Total Debt1.36M365K247K106K456K
Net Debt(40.83M)(17.76M)(936K)(3.62M)(3.55M)

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.